Why Chronic Lymphocytic Leukemia Is Often Watched First, and What Triggers Treatment

The word leukemia lands like a dropped plate. Then, almost in the same breath, the hematologist says something that sounds impossible: we are not going to treat this right now. Most people leave that first appointment holding two ideas that refuse to sit together. I have cancer. I am not being treated. Family members ask what the plan is, and “we are checking again in three months” does not feel like a plan.

Yet for chronic lymphocytic leukemia, or CLL, this is the standard of care, not neglect. Understanding the logic of CLL watch and wait treatment start decisions, meaning why doctors deliberately hold off and exactly what would change their minds, turns a frightening pause into something more like an informed agreement. The evidence behind it is unusually clear, and the triggers for treatment are written down in international guidelines rather than left to hunches.

This explainer walks through what monitoring involves, what “active disease” actually means, how long people commonly go without treatment, and which symptoms should never wait for the next scheduled visit.

What "watch and wait" actually means when you have CLL

CLL is a cancer of B lymphocytes, the white blood cells that normally make antibodies. In CLL, one clone of these cells keeps multiplying and, more importantly, refuses to die on schedule. The extra cells pile up in the blood, bone marrow, lymph nodes and spleen. Because the cells are mature-looking and accumulate slowly, many people have no symptoms at diagnosis; the condition is frequently found on a routine blood test ordered for another reason, according to MedlinePlus.

“Watch and wait,” sometimes called active monitoring or watchful waiting, is not the absence of care. It is a structured surveillance program. Your care team tracks specific measurements at regular intervals: the number of lymphocytes in your blood, hemoglobin (the oxygen-carrying protein in red cells), platelets (the fragments that help blood clot), the size of lymph nodes you or the doctor can feel, the size of the spleen, and a short list of whole-body symptoms.

The purpose is to catch the transition from indolent disease, where the cells are present but not causing harm, to active disease, where they crowd out normal blood production or produce symptoms that affect daily life. That transition, not the diagnosis itself, is what treatment is designed to address.

Think of it less like ignoring a leak and more like a structural engineer monitoring a hairline crack in a bridge. The crack is real. It is measured, photographed and compared visit to visit. Repairs begin when the measurements cross defined thresholds, because intervening on a stable crack introduces its own risks without adding strength. The thresholds for CLL come from the International Workshop on CLL, whose criteria are summarized in a guideline paper indexed on PubMed, and they form the backbone of everything that follows.

Why doctors don't treat CLL right away: what the evidence shows

The instinct to treat early is understandable. For many solid tumors, finding disease sooner and removing it improves outcomes. CLL behaves differently, and the difference has been tested rather than assumed.

Randomized trials going back decades compared people with early-stage CLL who started treatment immediately against people who were monitored and treated only when the disease became active. The National Cancer Institute’s patient summary on CLL states plainly that treating asymptomatic early-stage disease has not been shown to help people live longer, which is why observation is the standard approach for that group (NIH National Cancer Institute). This held true in the chemotherapy era and has been re-examined with newer targeted drugs; early treatment can delay progression on paper, but a survival advantage has not been demonstrated.

Meanwhile, every CLL treatment has a cost that is not measured in money. Infections become more likely because the treatments suppress the immune system further. Some therapies carry risks to the heart rhythm, bleeding tendency, kidneys or blood counts. Starting a person on years of therapy to treat a number that is not hurting them exposes them to those risks without a proven benefit on the outcome that matters most.

There is a second, subtler reason. CLL is a disease of long time horizons, and the toolbox is finite. Using a treatment early can mean the disease learns to resist it earlier, leaving fewer options when active disease genuinely needs controlling. Holding treatment in reserve keeps the full range of choices available for the moment they are needed.

None of this means the wait is passive or forever. A substantial share of people diagnosed with CLL will eventually require treatment. The watch and wait phase simply ensures that treatment begins when it can do measurable good and not before.

Who is usually asked to wait, and who starts treatment sooner

The decision rests on stage and on activity, which are related but not identical. Two staging systems are widely used. The Rai system, common in the United States, and the Binet system, common in Europe, both sort people by how many areas of lymph tissue are enlarged and whether the bone marrow is still producing normal amounts of red cells and platelets (NIH National Cancer Institute).

People usually asked to wait have early-stage disease: a raised lymphocyte count with, at most, a few enlarged lymph nodes, normal hemoglobin, normal platelets and no troubling symptoms. This describes a large proportion of people at diagnosis, because CLL is so often picked up incidentally.

People who usually start treatment sooner have evidence that the marrow is failing (anemia or low platelets caused by the leukemia), bulky or rapidly enlarging nodes or spleen, or constitutional symptoms such as drenching night sweats, unexplained weight loss or fevers. Anyone whose lymphocyte count is climbing very quickly also moves toward treatment, regardless of stage.

Age and other health conditions shape the choice of treatment more than the decision to treat. An older person with heart disease and a younger person with none may both meet criteria for active disease at the same moment; what differs is which therapy suits them.

Genetic features of the CLL cells, tested from a blood sample, add nuance. Certain chromosome changes and mutations predict that the disease is more likely to progress and to progress sooner. Your team may use these to set the interval between visits or to prepare for treatment. On their own, however, unfavorable genetics are not a treatment trigger under current international guidelines; active disease still has to be demonstrated (PubMed). The treating team weighs all of this together with your preferences, and the decision remains theirs to make with you.

CLL watch and wait: when does treatment start?

The International Workshop on CLL sets out specific criteria for “active disease,” and treatment is generally recommended when at least one is present (PubMed). Knowing them removes much of the mystery from monitoring visits, because you can see what your team is measuring against.

What is measured	What counts as a treatment trigger	Why it matters
Hemoglobin and platelets	Progressive anemia or low platelets caused by marrow infiltration	Signals that leukemia cells are crowding out normal blood production
Spleen	Massive enlargement (about 6 cm or more below the rib margin), progressive growth, or symptoms from size	Causes pain, early fullness when eating, and destroys blood cells
Lymph nodes	Massive nodes (about 10 cm or more) or steadily growing clusters	Can press on structures and indicates expanding disease
Lymphocyte kinetics	Count rising by more than half within 2 months, or doubling in under 6 months	Rapid growth predicts imminent complications
Immune complications	Autoimmune destruction of red cells or platelets not controlled by standard measures	The leukemia is driving harmful antibodies
Symptoms	Weight loss over 10% in 6 months, fevers above 38.0°C for 2 or more weeks without infection, night sweats for over a month, or disabling fatigue	Shows the disease is affecting the whole body

Notice what is not on this list: the absolute lymphocyte count by itself. A count that is high but stable is not a reason to treat. The guideline also specifies that the doubling-time rule applies only once counts are already substantially raised, because small numbers can fluctuate misleadingly.

Notice, too, that several triggers involve the word “progressive.” A single low reading rarely settles the question. Your team will typically repeat tests, rule out infection or medication effects, and confirm a trend before recommending treatment. That patience is deliberate.

How long can CLL go without treatment?

This is the question families ask most, and honest answers come in ranges rather than promises. CLL is highly variable. Some people are monitored for many years and never need treatment; others meet the criteria within months of diagnosis.

The NHS notes that CLL usually develops slowly, that many people do not need treatment for months or years, and that a proportion never require it during their lifetime. The NIH National Cancer Institute similarly describes CLL as a disease that often gets worse slowly, with early-stage disease managed by observation.

Several factors shift where an individual falls in that range:

• Stage at diagnosis. The fewer areas involved and the healthier the marrow, the longer the typical interval before treatment.
• Growth rate. A lymphocyte doubling time measured in years behaves very differently from one measured in months.
• Genetic features of the leukemia cells. Some mutations and chromosome deletions are associated with earlier progression; others with prolonged stability.
• Age. CLL is mainly diagnosed in older adults; MedlinePlus notes it is rare before the sixth decade of life. For many people, the natural pace of the disease is slow relative to their overall health picture (MedlinePlus).

What this means practically: nobody can tell you at diagnosis exactly how long you will wait, and anyone who does is guessing. What your team can do is assign a risk category from your stage, blood work and genetics, then set a monitoring interval that matches it. Low-risk disease might be reviewed every six to twelve months once stability is established; higher-risk disease more often. Those intervals are typical patterns, not fixed rules, and your own team will adjust them as your results come in.

How do you know when CLL is progressing? Signs doctors and patients watch for

Progression in CLL is usually a slope rather than a cliff, and it shows up in two places: the laboratory and daily life. Doctors watch both, and you are an essential observer of the second.

In the blood tests, the earliest signal is often the trend line of the lymphocyte count plotted over several visits. A steady, gentle rise is expected and not alarming. A curve that steepens, or a count that jumps between two visits, prompts a closer look. The other laboratory signals are falling hemoglobin and falling platelets. These matter more than the lymphocyte count because they reflect what the disease is doing to the marrow, not just how many cells are circulating.

In the body, progression tends to announce itself through the lymph system and the constitutional symptoms listed in the guidelines. Enlarging lumps in the neck, armpits or groin; a sense of fullness or discomfort under the left ribs where the spleen sits; feeling full after only a few mouthfuls; soaking night sweats that require changing sheets; weight falling without effort; fevers with no obvious infection; and fatigue that is out of proportion to activity and does not lift with rest (Mayo Clinic).

Infections that come more often, last longer or need more than one course of treatment are another marker. They reflect the immune dysfunction that deepens as CLL advances, including falling levels of normal antibodies.

A practical habit helps here. Many people keep a simple log between visits: weight, any lumps and their rough size, sweats, fevers, energy on a rough scale. Bringing that record to appointments turns vague impressions into data your team can weigh alongside the blood work. It also stops the common trap of forgetting, in the calm of a clinic room, how bad the sweats were three weeks earlier. This is not self-diagnosis; it is contributing accurate observations to a decision your team will make.

What a monitoring visit involves, and what the following weeks usually look like

A typical watch and wait appointment is short and predictable, which is part of its reassurance. Expect a conversation about how you have felt since the last visit, with specific questions about sweats, fevers, weight, energy, infections and bleeding or bruising. Expect a physical examination focused on the lymph node regions in the neck, armpits and groin, and on the abdomen to feel for the liver and spleen. Expect a blood draw for a complete blood count, and often tests of kidney and liver function and immunoglobulin levels (Mayo Clinic).

Imaging scans are not routinely repeated during monitoring unless there is a specific reason, such as a node that cannot be assessed by hand or a symptom that needs explaining. Bone marrow biopsies are likewise reserved for particular questions, most often to work out whether low counts are caused by the leukemia or by something else.

After a first diagnosis, visits tend to be closer together, often every few months, so the team can establish how fast your disease moves. Once a stable pattern is clear, the interval usually stretches. Between visits, life is expected to carry on normally: work, travel, exercise and family commitments are not restricted by monitoring itself.

When results shift toward the treatment criteria, the following weeks change character. The team typically confirms the trend with repeat blood work, rules out infection or a medication as the cause of a low count, and orders the additional tests that guide treatment choice. These commonly include genetic studies on the CLL cells if they have not already been done, a heart assessment if a treatment with cardiac effects is being considered, and hepatitis screening, since some therapies can reactivate dormant infection. This preparation period often spans several weeks, and it is a normal part of moving from monitoring to treatment rather than a delay. Your team will explain the sequence for your situation.

Why a high white cell count alone doesn't start treatment

Few numbers frighten people with CLL more than the lymphocyte count, partly because it is the number that led to the diagnosis and partly because it can climb into ranges that look absurd on a lab report. Counts several times, even ten or twenty times, the upper limit of normal are common in CLL, and people understandably assume such a number must be dangerous in itself.

It usually is not. CLL lymphocytes are small, mature cells. Unlike the immature blasts of acute leukemia, they do not tend to clog blood vessels or thicken the blood at the counts typically seen in CLL. The international guidelines are explicit that a high or rising lymphocyte count, in the absence of the other criteria, is not by itself an indication for treatment (PubMed).

What matters is what those cells are doing elsewhere. Are they filling the marrow to the point that red cells and platelets cannot be made? Are they packing the spleen until it presses on the stomach? Are they producing the chemical signals that drive fevers, sweats and weight loss? The lymphocyte count is a rough proxy for tumor burden, but hemoglobin, platelets, node size, spleen size and symptoms are the direct measures of harm.

The speed of the rise carries more weight than the height. A count that doubles in under six months signals aggressive growth and does count toward treatment, as the table above shows. A count that is very high but has barely moved in two years signals the opposite.

A useful reframe for the waiting room: your team is not tracking how many cells there are. It is tracking whether the cells have started to cause damage, and how quickly they are increasing. Ask to see the trend plotted over time rather than fixating on the latest figure. Most people find the graph far less alarming than the number.

Staying well during CLL watchful waiting: infections, vaccines and skin

Even before treatment, CLL weakens the immune system in ways that are not visible on a routine count. Normal antibody production falls, and the remaining immune cells function less well. Infection is the most common serious complication across the whole course of CLL, and prevention starts during the monitoring phase.

Vaccination is the highest-yield step. The CDC advises that people with hematologic cancers should receive inactivated vaccines, including annual influenza and recommended pneumococcal vaccines, while generally avoiding live vaccines. The immune response to vaccines in CLL is often blunted, so your team may recommend particular formulations or timing. Discuss the schedule with them rather than assuming the standard adult calendar applies unchanged.

Skin cancer surveillance deserves more attention than it usually gets. People with CLL have a higher risk of skin cancers, including melanoma and squamous cell carcinoma, and these cancers can behave more aggressively in the setting of immune impairment. Sun protection and periodic skin checks are sensible, and any new or changing lesion should be examined promptly (Johns Hopkins Medicine).

Everyday infection sense matters: hand hygiene, prompt attention to fevers, dental care, and avoiding close contact with people who are acutely ill where practical. If you develop low immunoglobulin levels and recurrent infections, your team may discuss immunoglobulin replacement, a treatment that supplies pooled antibodies; that is a supportive measure and separate from treating the leukemia itself.

General health protects you too. Cardiovascular fitness, not smoking, moderate alcohol and a healthy weight all widen the range of treatment options later and improve tolerance if treatment begins. None of these steps slow the leukemia, and no diet or supplement has been shown to do so. Their value is in keeping you strong enough to weather whatever comes next.

What is the newest treatment for CLL, and what happens when treatment begins?

When the criteria for active disease are met, the conversation shifts from whether to treat to how. The landscape has changed substantially, and understanding the main classes helps you follow that conversation.

Targeted oral therapies now form the backbone of most first-line treatment. Two mechanisms dominate. BTK inhibitors block Bruton tyrosine kinase, an enzyme inside B cells that relays the survival signals CLL cells depend on; with the signal cut, the cells stop proliferating and gradually die. BCL-2 inhibitors act on a different vulnerability: CLL cells overproduce a protein called BCL-2 that prevents them from dying on schedule, and blocking it lets the cells undergo their natural programmed death (Mayo Clinic).

Monoclonal antibodies against CD20, a marker on the surface of B cells, flag the cells for destruction by the immune system and are often combined with the drugs above.

Chemoimmunotherapy, combining traditional chemotherapy with an antibody, was the previous standard and is used less often now, though it remains an option in specific circumstances.

Beyond these, treatments such as stem cell transplantation and cell-based immunotherapies exist for particular, usually relapsed, situations. Newer agents within the existing classes continue to be developed, and “newest” is a moving target; newer does not automatically mean better for a given person.

Treatment approaches differ in an important practical way. Some are taken continuously for as long as they work; others are given for a fixed period and then stopped. Side-effect profiles differ too: heart rhythm disturbances and bleeding tendency with some agents, a risk of rapid cell breakdown requiring careful monitoring at the start of others, and infection risk with all. Your team matches these features to your heart health, kidney function, other medicines and preferences. The choice of treatment, its timing and any later change belong entirely to that shared decision with your prescribing clinician.

CLL watch and wait treatment start: what people often get wrong

“Watch and wait means they’ve given up on me.” The opposite is true. Monitoring is chosen because trials show early treatment does not extend life and does add harm (NIH National Cancer Institute). It preserves your options and your quality of life for as long as possible.

“If the count goes up, I’ll need treatment.” A rising count is expected. Only a rapid rise, defined by the doubling-time criteria, contributes to the decision, and never on its own.

“Treatment would get rid of the leukemia, so waiting lets it grow.” Current treatments control CLL, often for long periods, but the disease typically remains and can return. Treating a stable, symptom-free person early has not been shown to change the long-term picture, while exposing them to years of side effects.

“Diet or supplements can hold it back.” No food, herb or supplement has been demonstrated to slow CLL. Some supplements interact with future treatments or affect liver and kidney function. Tell your team about anything you take.

“Feeling fine means nothing is happening.” Marrow involvement and node growth can progress quietly. That is precisely why blood tests and examination continue even when you feel well.

“Feeling tired means it’s progressing.” Fatigue is one criterion, but only when it is severe, persistent and not explained by anything else. Ordinary tiredness, poor sleep, anemia from other causes, thyroid problems and mood all need excluding first.

“Once treatment starts, it never stops.” Some regimens are fixed-duration by design, followed by a return to monitoring.

“CLL is the same in everyone.” It is one of the most variable cancers there is. Comparing your course with someone in an online group is rarely informative and often distressing. Your genetics, stage and growth rate make your situation your own.

Living with the uncertainty of not being treated

The clinical logic of monitoring is sound, but logic does not always quiet a racing mind at two in the morning. Many people describe the watch and wait period as harder emotionally than they expected, and some find it harder than treatment itself. The cancer is named but not fought; the calendar is marked with blood tests that feel like verdicts. The NHS acknowledges that living with a condition that is monitored rather than treated can be a source of anxiety and that support is part of good care.

A few approaches help, drawn from what people with CLL and their teams commonly report.

Reframe the appointments. Each visit that shows stability is a data point in your favor, not a near miss. Asking to see your results plotted over time makes stability visible in a way single numbers never do.

Decide how much to read. Understanding the treatment criteria, as you are doing now, reduces fear because it replaces vague dread with a checklist your team is working through. Reading about every possible complication or every new trial tends to do the reverse.

Tell people what you need. Family and friends often want to help by urging action: get a second opinion, try this diet, push for treatment. Explaining that the plan is deliberate, and that what you need is company at appointments or patience on tired days, redirects that energy usefully.

Watch for depression and persistent anxiety, and raise them with your team. They are common, they are treatable, and they are not a sign of coping badly. Hematology services can usually connect you with counseling or support groups for people with blood cancers.

Keep the parts of life that are not about CLL. Work, exercise, travel and hobbies are not restricted by monitoring, and continuing them is not denial; it is the point of choosing to wait.

Questions to ask your care team during watch and wait

Appointments are short and the questions that matter most tend to surface in the car afterward. Writing them down beforehand, and bringing someone to take notes, changes that. These are the questions people with CLL commonly find most useful.

• What stage is my CLL, and which of the treatment criteria are you tracking most closely in my case?
• Have genetic tests been done on my CLL cells? What did they show, and how do they affect how often you want to see me?
• What is my lymphocyte doubling time so far, and can I see the trend of my counts over time?
• Are my hemoglobin and platelets stable? If they fall, how will you work out whether the leukemia or something else is responsible?
• Which symptoms should prompt me to contact you before my next scheduled visit, and how do I reach the team quickly?
• Which vaccines do you recommend for me, and are there any I should avoid?
• Should I have regular skin checks, and who should do them?
• Are there medicines, supplements or activities I should avoid or tell you about?
• If treatment becomes necessary, what would the likely options be for someone with my health profile, and what preparation would be needed?
• Would I be a candidate for any clinical trials, either now or when treatment begins?
• Who else is on my team, such as a specialist nurse or pharmacist, and what can they help with between visits?
• How will you and I decide together when the time to start treatment has arrived?

You are entitled to clear answers, and to ask for them again if the first explanation did not land. Many people also find it useful to request copies of their blood results so they can keep their own record. A team that knows you understand the criteria can have franker, faster conversations with you when the picture changes (Mayo Clinic).

When to call your doctor: red-flag signs that should not wait for your next visit

Scheduled monitoring catches slow change. Some developments should prompt a call to your hematology team the same day, and a few warrant emergency care. Contact your team promptly if you notice any of the following (NHS; Mayo Clinic):

• A fever, or chills and shaking, especially without an obvious cause. Infections can progress quickly when the immune system is impaired, and a fever in someone with CLL deserves same-day medical assessment.
• Unusual bleeding or bruising: nosebleeds that will not stop, bleeding gums, blood in urine or stool, or widespread pinpoint red spots on the skin. These can signal falling platelets.
• Sudden breathlessness, chest pain, a racing or irregular heartbeat, or feeling faint. These may indicate severe anemia, infection or a heart problem and need urgent evaluation.
• A lymph node that has grown quickly over days to weeks, or a node that is hard, fixed or painful.
• New pain or fullness under the left ribs, or pain in the left shoulder, which can come from a swollen spleen. Severe abdominal pain after a knock or fall needs emergency care because an enlarged spleen can rupture.
• Drenching night sweats, unexplained weight loss or fevers that persist over more than a couple of weeks.
• Yellowing of the skin or eyes, or very dark urine, which can reflect red cells being destroyed.
• Severe or worsening fatigue that stops you doing everyday tasks.
• Any new or changing mole or skin lesion.
• Confusion, a severe headache, a stiff neck or a rash that does not fade under pressure, which need emergency assessment for serious infection.

None of these signs confirms that your CLL is progressing; several have other explanations. The point of calling is to let your team decide quickly what needs checking. Keep the team’s contact details, including out-of-hours arrangements, somewhere you and those close to you can find them. When in doubt, call.

Frequently asked questions

At what point does treatment start for CLL?

Treatment usually starts when CLL becomes active according to international criteria: progressive anemia or low platelets from marrow involvement, massive or rapidly growing lymph nodes or spleen, a lymphocyte count doubling in under six months, autoimmune complications that do not respond to standard measures, or persistent fevers, night sweats, weight loss or disabling fatigue. A high count alone does not qualify. Your hematology team confirms the trend before recommending treatment.

How long can CLL go without treatment?

Often for months to many years, and some people never need treatment in their lifetime. The range is wide because CLL varies so much between individuals. Stage at diagnosis, how quickly the lymphocyte count rises, and genetic features of the leukemia cells all influence the interval. Your team can place you in a risk category and set a monitoring schedule, but nobody can predict an exact timeline.

How do you know when CLL is progressing?

Progression shows up in blood trends and in the body. Doctors watch for a steepening lymphocyte curve, falling hemoglobin and falling platelets. Physical signs include enlarging lymph nodes, fullness or discomfort under the left ribs from the spleen, drenching night sweats, unexplained weight loss, fevers without infection, disproportionate fatigue and more frequent infections. Keeping a simple log of these between visits helps your team assess change accurately.

What is the newest treatment for CLL?

The most recent generation of CLL treatments are targeted oral drugs: BTK inhibitors, which block a survival-signaling enzyme inside B cells, and BCL-2 inhibitors, which remove a protein that stops CLL cells dying. These are often combined with anti-CD20 antibodies. Newer agents within these classes continue to emerge, but newest does not mean best for every person; your team matches treatment to your heart health, kidneys, other medicines and preferences.

What are the signs CLL is progressing that I should report between visits?

Report new or fast-growing lumps in the neck, armpits or groin; fullness or pain under the left ribs; night sweats that soak bedding; weight loss without trying; fevers with no clear cause; fatigue that stops normal activity; frequent or prolonged infections; and unusual bruising or bleeding. Any fever in someone with CLL should be assessed the same day, because infections can escalate quickly when immunity is impaired.

Does watchful waiting for CLL mean my doctors are doing nothing?

No. Watchful waiting is active surveillance with a defined purpose: to detect the shift from stable to active disease and begin treatment at the moment it can do measurable good. It involves regular blood counts, physical examinations and symptom reviews. Trials have shown that treating symptom-free early-stage CLL does not extend life while adding side effects, so monitoring protects both your quality of life and your future treatment options.

Why don't doctors treat my high white blood cell count?

Because CLL lymphocytes are small, mature cells that rarely cause harm through sheer number at the counts typically seen. What matters is whether they are crowding out red cells and platelets in the marrow, enlarging nodes or the spleen, or driving whole-body symptoms. International guidelines state that a high or rising count alone is not a treatment indication; only a rapid doubling time counts, and never in isolation.

How often will I have blood tests during CLL watch and wait?

Typically every few months after diagnosis, while your team establishes how quickly your disease moves, then less often once stability is clear, sometimes every six to twelve months for low-risk disease. Higher-risk features or a changing trend shorten the interval. Each visit usually includes a complete blood count, a physical examination of nodes and spleen, and a review of symptoms. Scans and marrow biopsies are not routine during monitoring.

Can diet, exercise or supplements slow CLL during watch and wait?

No diet, supplement or exercise program has been shown to slow CLL. General good health does matter, though: staying active, not smoking, protecting your skin from the sun and keeping vaccinations current improve your ability to tolerate treatment later and reduce infection risk. Some supplements can interact with future treatments or affect liver and kidney function, so tell your team about anything you take.

Which vaccines should I have if I have CLL and have not started treatment?

Guidance for people with blood cancers recommends inactivated vaccines, including annual influenza and the recommended pneumococcal vaccines, and generally advises against live vaccines because immune function is impaired. Responses to vaccines are often weaker in CLL, so your team may suggest particular formulations or timing, especially if treatment is approaching. Discuss your full vaccination schedule with your hematology team rather than assuming the standard adult schedule applies.

References

• iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (PubMed)
• Chronic lymphocytic leukaemia, NHS
• Chronic lymphocytic leukemia (CLL), MedlinePlus Medical Encyclopedia
• Altered Immunocompetence: General Best Practice Guidelines for Immunization, CDC

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.